Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Down 17.4% in January

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a large drop in short interest in January. As of January 30th, there was short interest totaling 255,701 shares, a drop of 17.4% from the January 15th total of 309,450 shares. Based on an average daily trading volume, of 485,071 shares, the days-to-cover ratio is currently 0.5 days. Approximately 1.7% of the company’s shares are sold short. Approximately 1.7% of the company’s shares are sold short. Based on an average daily trading volume, of 485,071 shares, the days-to-cover ratio is currently 0.5 days.

Marker Therapeutics Price Performance

Marker Therapeutics stock traded up $0.02 during trading hours on Tuesday, reaching $1.45. The stock had a trading volume of 85,669 shares, compared to its average volume of 360,355. The company has a market cap of $24.17 million, a price-to-earnings ratio of -1.18 and a beta of 1.44. The business’s 50 day moving average price is $1.64 and its 200-day moving average price is $1.26. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.07.

Institutional Investors Weigh In On Marker Therapeutics

Several institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in shares of Marker Therapeutics during the fourth quarter worth $60,000. Boyer Financial Services Inc. purchased a new position in Marker Therapeutics during the 4th quarter worth $57,000. Two Sigma Investments LP purchased a new position in Marker Therapeutics during the 3rd quarter worth $33,000. Geode Capital Management LLC increased its position in Marker Therapeutics by 35.3% during the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after buying an additional 34,028 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Marker Therapeutics in the third quarter valued at about $25,000. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MRKR has been the subject of several research analyst reports. HC Wainwright assumed coverage on shares of Marker Therapeutics in a research note on Monday, December 8th. They set a “buy” rating and a $10.00 price target for the company. UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a research report on Monday, December 8th. Wall Street Zen raised Marker Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Monday, December 22nd. Finally, Zacks Research downgraded Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.